Healthcare Sector — Q1 FY26 Earnings Overview
4 companies reported. 3 bullish, 1 neutral, 0 bearish.
Average revenue growth: 11.0%
Sector sentiment: bullish
Aggregate revenue: ₹32,427 Cr
Average margin: 21.7%
Company Results
| Company | Revenue | YoY | Margin | Sentiment |
|---|---|---|---|---|
| Sunpharma | ₹13,786 Cr | +10.1% | 31.1% | bullish medium |
| Cipla | ₹6,957 Cr | +4% | 25.6% | neutral medium |
| Apollo Hospitals Enterprise | ₹5,842 Cr | +15% | 15.0% | bullish high |
| Apollohosp | ₹5,842 Cr | +15% | 15.0% | bullish high |
Key sector risks this quarter
Sunpharma · high
Halol, Mohali, and Dadra facilities remain under FDA warning letters, limiting generic approvals and U.S. supply flexibility.
Cipla · highManagement could not provide precise timing of Revlimid revenue decline, which may impact quarterly US revenue and margins.
Cipla · highIndore facility is due for US FDA reinspection within the next year; any adverse outcome could disrupt US supplies.
Apollo Hospitals Enterprise · mediumQuick-commerce players have entered the prescription business with aggressive discounts, potentially pressuring margins and customer acquisition costs.
Apollo Hospitals Enterprise · mediumInternational patient volumes from Bangladesh remain below pre-disruption levels, though case complexity has increased.